BONSITY

Peak

teriparatide

NDASUBCUTANEOUSSOLUTION
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

84-amino acid parathyroid hormone (PTH) is the primary regulator of calcium and phosphate metabolism in bone and kidney. Physiological actions of PTH include regulation of bone metabolism, renal tubular reabsorption of calcium and phosphate, and intestinal calcium absorption. The biological actions…

Pharmacologic Class:

Parathyroid Hormone Analog

Clinical Trials (5)

NCT07081997Phase 3Not Yet Recruiting

A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

Started Apr 2026
36 enrolled
HypoparathyroidismEndocrine System DiseasesParathyroid Diseases
NCT07345494N/ARecruiting

A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

Started Feb 2026
50 enrolled
Hypoparathyroidism
NCT07264634N/ANot Yet Recruiting

A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)

Started Jan 2026
10 enrolled
Hypoparathyroidism
NCT04589819Phase 4Enrolling By Invitation

Fracture Recovery for Returning to Duty (Teriparatide STRONG)

Started Dec 2022
183 enrolled
Stress Fracture of Tibia or Fibula
NCT05369013N/AUnknown

Study and Follow-up of the Clinical Effectiveness and Comparative Safety of Biosimilar Teriparatide in the Management of Postmenopausal or Senile.

Started Jun 2021